Le rôle unique du médecin de famille dans la prise en charge de l’insuffisance cardiaque
Résumé
L’insuffisance cardiaque (IC) est une épidémie dont le pronostic est pire que celui de certains cancers. La prévention, le diagnostic précoce, la coordination et la mise en œuvre d’un traitement médical optimisé selon les lignes directrices sont impératifs pour endiguer ce tsunami. Le médecin de famille se trouve dans une position unique, critique et de première ligne pour être en mesure d’offrir ces trois éléments. Sa compréhension et la mise en œuvre de ces rôles sont cruciales pour le succès de la lutte contre l’IC. Cette analyse offre une perspective sur le rôle des médecins de famille dans la prise en charge de l’IC.
Références
Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Eur J Heart Fail. 2021; 23:352-380. doi:10.1016/j.cardfail.2021.01.022
Bozkurt, B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, et al. Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America. J Card Fail. 2023; 29(1):1412-1451. doi:10.1016/j.cardfail.2023.07.006
Canadian Chronic Disease Surveillance System (CCDSS) [Date modified: 2024 March 20]. Public Health Agency of Canada, Health Infobase https://health-infobase.canada.ca.
Moghaddam N, Lindsay P, Hawkins NM, Anderson K, Ducharme A, Lee, DS, et al. Access to heart failure services in Canada: findings of the Heart and Stroke National Heart Failure Resources and Services Inventory. Can J Cardiol. 2023;39(10):1469-1479. doi:10.1016/j.cjca.2023.06.430
Poon S, Leis B, Lambert L, MacFarlane K, Anderson K, Blais C, et al. The state of heart failure care in Canada: minimal improvement in readmissions over time despite an increased number of evidence-based therapies. CJC Open. 2022;4: 667-675. doi:10.1016/j.cjco.2022.04.011
Heart and Stroke Foundation. Falling Short: How Canada is Failing People with Heart Failure—and How We Can Change That. https;//heartstroke.ca/-/media/pdf-files/canada/2022-heart-month/hs-heart-failure-report-2022-final.pdf.
Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. 2019; 21(11):1306-1325. doi:10.1002/ejhf.1594
Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline and reduced ejection fraction 5-year outcomes. J Am Coll Cardiol. 2017;70:2476-2486. doi:10.1016/j.jacc.2017.08.074
Yeung DF, Boom NK, Guo H, Lee DS, Schultz SE, Tu JV. Trends in incidence of outcomes of heart failure in Ontario, Canada:1997 to 2007. CMAJ. 2012;184 (14):765-773. doi:10.1503/cmaj.111958
Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154(2):260-266. doi:10.1016/j.ahj.2007.01.041
Blecker S, Kunihiro M, Kottgen A, Loehr LR, Bertoni AG, Boulware LE, et al. High-normal albuminuria and risk of heart failure in the community. Am J Kidney Dis. 2011; 58(1):47-55. doi:10.1053/j.ajkd.2011.02.391
Tao J, Sang D, Zhen L, Zhang X, Li Y, Wang G, et al. Elevated urine albumin-to-creatinine ration increases the risk of new-onset heart failure in patients with type 2 diabetes. Cardiovasc Diabetol. 2023;22(1):70. doi:10.1186/s12933-023-01796-6
Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. 2009;374 9689):543-550. doi:10.1016/S0140-6736(09)61378-7
Mueller C, McDonald K, de Boer, RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-731. doi:10.1002/ejhf.1494
Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RRJ, Lainchbury JG, Richards AM, Ordonez-Llanos J, et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med. 2007;167(4):400-407. doi:10.1001/archinte.167.4.400
Tilson L, Tallon E, O’Connell E, Maurer B, Gallagher J, Murtagh G, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310(1):66-74. doi:10.1001/jama.2013.7588
Huelsmann, M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol. 2013;62(15):1365-1372. doi:10.1016/j.jacc.2013.05.069
Ezekowitz JA, O’Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. 2017;33(11):1342-1433. doi:10.1016/j.cjca.2017.08.022
Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction (GUIDE-IT). JAMA. 2017;318(8):713-720. doi:10.1001/jama.2017.10565
McLellan J, Bankhead CR, Oke JL, Hobbs FDR, Taylor CJ, Perera R. Natriuretic peptide-guided treatment for heart failure: a systematic review and meta-analysis. BMJ Evid Based Med. 2020; 5(1):33-37. doi:10.1136/bmjebm-2019-111208
McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz J, Giannetti N, et al. CCS/CHFS Heart Failure Guidelines Update: defining a new pharmacologic standard of care of heart failure with reduced ejection fraction. Canadian J Cardiol. 2021;37(4):531-546. doi:10.1016/j.cjca.2021.01.017
McDonagh TA, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36): 3599-3726. doi: 10.1093/eurheartj/ehab368. [published correction appears in Eur Heart J. 2021 Dec 21;42(48):4901. doi: 10.1093/eurheartj/ehab670]. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022145:e895-e1032. doi: 10.1161/CIR.0000000000001073] [published correction appears in Circulation. 2022 Sep 27;146(13):e185. doi: 10.1161/CIR.0000000000001097] [published correction appears in Circulation. 2023 Apr 4;147(14):e674. doi: 10.1161/CIR.0000000000001142]. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063
McMurray JJV, Packer MP. How should we sequence the treatments for heart failure and a reduced ejection fraction? A redefinition of evidence-based medicine. Circulation. 2021;143(9):875-877. doi:10.1161/CIRCULATIONAHA.120.052926
Greene SJ, Bulter J, Fonarow GC. Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure—optimizing therapy with the need for speed. JAMA Cardiol. 2021;6(7):743-744. doi:10.1001/jamacardio.2021.0496
Bassi, NS, Ziaeian B, Yancy CW, Fonarow GC. Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure. JAMA Cardiol. 2020; 5(8): 948-951. doi:10.1001/jamacardio.2020.0898
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. [published correction appears in N Engl J Med. 2019 Mar 14;380(11):1090. doi: 10.1056/NEJMx190009]. N Engl J Med. 2019;380(6):539-548. doi:10.1056/NEJMoa1812851
DeVore AD, Braunwald E, Morrow DA, Duffy CI, Amrosy AP, Chakraborty H, et al. Initiation of angiotensin-neprilysin inhibition after acute decompensated heart failure; secondary analysis of the open-label extension of the PIONEER-HF trial. JAMA Cardiol. 2020;5(2):202-207. doi:10.1001/jamacardio.2019.4665
Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patents hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574. doi:10.1038/s41591-021-01659-1
Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies of acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022; 400(10367):1938-1952. doi:10.1016/S0140-6736(22)02076-1
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. [published correction appears in Eur Heart J. 2024 Jan 1;45(1):53. doi: 10.1093/eurheartj/ehad613]. Eur Heart J. 2023;44(37):3627-3639. doi:10.1093/eurheartj/ehad195
Halliday BP, Wassall R, Lata AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open label, pilot, randomised trial. Lancet. 2019;393:61-73. doi:10.1016/S0140-6736(18)32484-X
Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963
Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390:1394-1407. doi:10.1056/NEJMoa2313917
Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Chang-Sheng M, Chiang CE, Cioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee APW, Linssen GCM, Llamas-Esperon G, Mareev V, Martinez FA, Melenovsky V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P. NEJM September 1, 2024 DOI: 10.1056/NEJMoa2407107
Petrie M, Borlaug B, Buckholtz K, Ducharme A, Hvelplund A, Lam CSP, et al. HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. Journal of Cardiac Failure. 2024;30(1) P126. https://doi.org/10.1016/j.cardfail.2023.10.024
Publié
Comment citer
Numéro
Rubrique
Licence
© Canadian Primary Care Today 2024
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
